CN1162467A - External use medicine for curing scars - Google Patents
External use medicine for curing scars Download PDFInfo
- Publication number
- CN1162467A CN1162467A CN96115229A CN96115229A CN1162467A CN 1162467 A CN1162467 A CN 1162467A CN 96115229 A CN96115229 A CN 96115229A CN 96115229 A CN96115229 A CN 96115229A CN 1162467 A CN1162467 A CN 1162467A
- Authority
- CN
- China
- Prior art keywords
- medicine
- cicatrix
- external use
- borneolum syntheticum
- crude drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
An exterior-used filming medicine for preventing and curing the scars resulted from burn, scald trauma and operation is prepared from 12 Chinese-medicinal materials such as Chuan-Xiong rhizome, Chinese angelica root, peach kernel, safflower, pangolin scales, etc., as well as dexamethasone.
Description
The present invention relates to a kind of medicine for external use for the treatment of cicatrix, have blood circulation promoting and blood stasis dispelling, hard masses softening and resolving, detumescence, pain relieving, separate the effect of itching.Can be used for preventing and treating the various cicatrixes that produce behind the skin healings such as burn and scald, wound, operation.
The wound healing process is divided into the phase of oozing out, propagation phase, cicatrization phase.Show as that vasodilation, permeability increase, water, electrolyte etc. ooze out, leukocyte infiltration the phase of oozing out, as damage seriously, the inflammation performance can be for several weeks.The a large amount of hypertrophy of propagation phase fibroblast, and synthetic a large amount of collagen fiber etc.; Fibroblast is ripe in collagen, becomes fibrocyte, and constantly breeding forms connective tissue; The rapid hypertrophy of vascular endothelial cell forms abundant capillary network.Newborn collagen fiber, capillary network, fibroblast and inflammatory cells etc. have constituted the main component of granulation tissue.Cicatrization phase wound is filled by little and mixed and disorderly collagen bundle gradually, and these fibre bundles increase gradually, chap, and row is split the fine and close cicatrix that forms.
Behind the wound healing, it is a chronic inflammatory disease process that scar tissue continues hypertrophy, and all scar tissues, dark or shallow its volume in several years and shape are all constantly changing.Collagen tissue continues the higher synthetic ratio of maintenance, and the synthesis and degradation imbalance, and sedimentary collagen and fibrous tissue are shunk gradually, newborn epithelium degeneration, myofibroblast continues hypertrophy, and its result causes scar hyperplasia, contraction or contracture, and this phase can continue several months even several years.
After forming cicatrix, bring infringement usually with in various degree dysfunction, or to organ dysfunction, or influence the attractive in appearance of appearance, make the patient bear the human body or spiritual misery.Have only corresponding cosmetics for this disease existing market, as the close beautiful cicatrix spirit of southern Mi County elixir of life laboratory, the beautiful cicatrix cream in kylin pharmaceutical factory, Hong Kong.
Described a kind of treatment skin scar increament and Pigmented ointment at Chinese patent 93115881.8, its prescription consists of Rhizoma Typhonii, the Radix Angelicae Dahuricae, Radix Ampelopsis, Lithargyrum, red medicine, Flos Chrysanthemi, Bulbus Fritillariae Cirrhosae, Semen phaseoli radiati powder and Pulvis Talci.
Also have report: " cicatrix ointment for softening " is (by Shandong science tech publishing house, published in 1981, chief editor such as Zhao Tianen " the 268th page of department of dermatologry external used medicine handbook), its prescription is made up of zinc oxide, gelatin, glycerol, Galla Chinensis, Scolopendra, Borneolum Syntheticum and Camphora." compound Chinese Gall preserved material " (the 20th page of " doctor studies magazine " 1989 the 3rd phase that Liu Jing writes) prescription contains Galla Chinensis, Scolopendra, Flos Carthami, Radix Glycyrrhizae etc.
The objective of the invention is to develop a kind of medicine for external use that determined curative effect has no side effect again on treatment cicatrix disease, on therapeutic effect, be better than the cicatrix ointment for softening (by the military region, Shenyang shaping microsurgery Research Institute, lot number is 1994 in the army, No. the 9th, Shen system stream word, Shen system FPSZ0659 number) application forms.
According to theory of Chinese medical science, the cicatrix of skin is because battalion defends and becomes estranged, and mechanism of qi is stopped up resistance and the blood stasis that causes, or the QI and blood stasis of blood forms in skin, the clinical manifestation redness, bitterly, the symptom of itching.Thereby medicine for external use of the present invention has selected to have blood circulation promoting and blood stasis dispelling, hard masses softening and resolving, detumescence, pain relieving, separate the Chinese medicine of the function of itching, it is equipped with Squama Manis, Olibanum, Myrrha, reaches Borneolum Syntheticum composition Chinese medicine ingredients based on Rhizoma Chuanxiong, Radix Angelicae Sinensis, Semen Persicae, Flos Carthami, Radix Salviae Miltiorrhizae, Galla Chinensis, Radix Sophorae Flavescentis, Pseudobulbus cremastrae seu pleiones.
The present invention treats the medicine for external use of cicatrix, be characterized in forming (percentage by weight) by extract, dexamethasone acetate 0.001～0.01% and all the other adjuvant (solvent or substrate etc.) of Borneolum Syntheticum 0.2～1.5%, crude drug 10～60%, wherein crude drug constitutes (part by weight) in following ratio composition:
Rhizoma Chuanxiong 20～40; Radix Angelicae Sinensis 10～30; Semen Persicae 10～30; Flos Carthami 5～25; Squama Manis 2～20; Olibanum 2～10; Myrrha 2～10; Radix Salviae Miltiorrhizae 30～50; Radix Sophorae Flavescentis 10～30; Pseudobulbus cremastrae seu pleiones 15～35; Galla Chinensis 5～25.
Medicine for external use of the present invention, crude drug, Borneolum Syntheticum powder can be become fine powder (crossing 100 mesh sieves) to make ointment in the type substrate with dexamethasone acetate adding (O/W) type or (W/O), or with crude drug coarse powder usefulness ethanol (75%) immersion 3～10 days, get that preserved material adds Borneolum Syntheticum, dexamethasone acetate is made tincture, can also make water preparation, tincture, ointment, patch or liniment with adding Borneolum Syntheticum fine powder, dexamethasone acetate powder and adjuvant (solvent, substrate, auxiliary agent etc.) behind crude drug water or the ethanol extraction.
In order to develop best application forms; a large amount of experiments have been carried out; the experiment initial stage is made tincture, ointment with Chinese medicine; undesirable through observation of curative effect; make rubber-emplastrum later on again, because bonding force is too big, can be when changing dressings with the avulsion of cicatrix epidermis; cause new wound surface; after change patch again into because dosage form is coarse, bonding force is too little; clinical use inconvenience; made this dosage form of liniment (membrane removal of title Scar eliminating medicine or cicatrix are filmed) at last behind coating, the solvent volatilization forms thin film, has both protected wound surface; medicine is discharged gradually, keep the long period curative effect.
The present invention treats the liniment of cicatrix, is characterized in being grouped into (percentage by weight) by the one-tenth of following quantitative proportion:
10～60% extracts from crude drugs, Borneolum Syntheticum 0.2～1.5%, dexamethasone acetate 0.001～0.01%, laurocapram 0.5～1.5%, polyvinyl butyral resin 9～12%, dibutyl phthalate 2～5%, glycerol 5～10%, acetone 5～10%.
Preparation method: the crude drug each component is ground into coarse powder, take by weighing each component in crude drug each component ratio and formula proportion, the dress percolator after 24 hours, is made solvent with ethanol with alcohol dipping, speed percolation with 2～5ml/ branch, collect percolate to 300% of product full dose, decompression recycling ethanol (50～60 ℃), being concentrated into relative density is the clear paste of 1.10～1.20 (50～60 ℃ of heat are surveyed), add ethanol to 50% of product full dose, mixing.Add other component by formula proportion, under constantly stirring, add ethanol, promptly get product to full dose.
Use the liniment of the embodiment of the invention 3, carrying out relevant pharmacodynamic study with the animal wound healing model proves: have following effect: 1. analgesic activity; 2. anti-hamartoplasia, antiinflammatory action; 3. itching-relieving action; 4. the effect of anti-burn property and incised wound scars hypertrophy, contracture.
More than effect all significantly is better than positive control drug " cicatrix ointment for softening " (use lot number army in: 1994, Shen system flows font size No. 9, Shen system FPSZ0659 number).
Chinese medicine and dexamethasone compatibility, collaborative playing a role, more than the intensity of four effects, the two share obviously be better than single with the liniment of Chinese medicine with only with the liniment of dexamethasone.
Pharmacological research shows, after cicatrix after the rats after burn and the medication of Cavia porcellus incised wound cicatrix, through tissue detection, the liniment of proof embodiment 3 reduces inflammatory cell infiltration in the scar tissue, brings into play its inhibition scar tissue hypertrophy, contracture effect by suppressing fibroblast in the scar tissue, blood capillary, granulation tissue hyperplasia, obviously reducing the scar tissue collagen contents.
The liniment of embodiment 3, by to the guinea pig skin acute toxicity test, illustrate skin complete Cavia porcellus, skin injury Cavia porcellus are not all caused toxic reaction at aspects such as skin, hair, eyes, mucosa, behavior sign, extremity activity, central nervous system, body weight, heart rate, breathings.By long term toxicity test to animal, comprise skin irritation test to rabbit, to the guinea pig skin sensitivity test with to the rat long term toxicity test, prove the rabbit intact skin is had no stimulation that damaged skin is had the property a crossed minimal irritation; The test Cavia porcellus is not caused skin allergy, do not cause systemic anaphylaxis yet, by intact skin rat, damaged skin rat were tried in three months, many index detects, body weight, routine blood test, liver function, renal function to rat do not have any harmful effect, are not had pathologic and damage trying skin, heart, liver, spleen, lung, kidney.Show with every g to contain crude drug 0.21g, the concentration clinical application of dexamethasone acetate 0.0646mg can not cause toxic reaction, and improving three times of concentration also is the safe drugs concentration dose.
The liniment of embodiment 3 is by unit clinical observation on the therapeutic effect 100 examples such as No. 1 Hospital Affiliated to Chinese Medical Univ, through the treatment of 4 weeks, antipruritic effective percentage 87%, pain relieving effective percentage 86%, aggregative indicator obvious effective rate 73%, effective percentage 25%.Point out clinical observation 215 examples, cure rate 54.9%, total effective rate 97.1% through the report of Anshan iron and steel plant burn shaping institute.Through unit clinical observation 46 examples such as first Affiliated Hospital of Xinjiang Shihezi Medical College, cure rate 76% in three months internal therapies, total effective rate 92%.
Below by embodiment the present invention is described in more detail:
Embodiment 1
Rhizoma Chuanxiong 60g Radix Angelicae Sinensis 40g Semen Persicae 40g Flos Carthami 30g Squama Manis 25g Radix Salviae Miltiorrhizae 80g Pseudobulbus cremastrae seu pleiones 50g Galla Chinensis 20g Radix Sophorae Flavescentis 40g Olibanum 10g Myrrha 10g dexamethasone acetate 0.05g Borneolum Syntheticum 10g ethanol (75%) is made 1000g
With the above-mentioned dexamethasone acetate that removes, the crude drug powder outside the Borneolum Syntheticum becomes coarse powder, adds ethanol (75%) to 1000g, in 10～30 ℃ of immersions 5 days, filters, and gets filtrate and adds Borneolum Syntheticum (being ground into fine powder, with small amount of ethanol dissolving, filtration), dexamethasone acetate, promptly gets product.
Embodiment 2
Rhizoma Chuanxiong 60g Radix Angelicae Sinensis 45g Semen Persicae 40g flower 32g Squama Manis 25g Radix Salviae Miltiorrhizae 70g Pseudobulbus cremastrae seu pleiones 48g Galla Chinensis 16g Olibanum 10g Myrrha 10g Radix Sophorae Flavescentis 40g Borneolum Syntheticum 10g dexamethasone acetate 0.075g stearic acid 215g Cera Flava 36g triethanolamine 12g glycerol 19g distilled water 870g.
Getting crude drug puts in the extraction pot, extracting in water twice, each 2 hours, merge extractive liquid, was evaporated to the thick paste shape, add triethanolamine, glycerol, distilled water, stir, be heated to 70 ℃, add the stearic acid and the Cera Flava (in water-bath, be heated to 70 ℃ and make whole fusings) of fusing then slowly, constantly be stirred to condensation to a direction, add Borneolum Syntheticum powder again, the dexamethasone acetate mixing promptly gets product.
Embodiment 3
Rhizoma Chuanxiong 32g Radix Angelicae Sinensis 20g Semen Persicae 20g Flos Carthami 16g Squama Manis 12g Olibanum 4g Myrrha 4g Radix Salviae Miltiorrhizae 40g Pseudobulbus cremastrae seu pleiones 24g gall nut 8g Radix Sophorae Flavescentis 20g Borneolum Syntheticum 8g dexamethasone acetate 0.0646g laurocapram 10g dibutyl phthalate 32g glycerol 80g acetone 80g polyvinyl butyral resin 105g ethanol (95%) adds to 1000g.
Get Rhizoma Chuanxiong etc. ten crude drug simply, be ground into coarse powder, according to percolation under the fluid extract item (17 pages of appendix of Chinese Pharmacopoeia nineteen ninety version) percolation, make solvent with ethanol, flood 24 hours (10～30 ℃) after, speed percolation with the about 3ml of per minute, collect the about 3000g of percolate, decompression recycling ethanol (50～60 ℃), and to be concentrated into relative density be 1.14～1.16 (50～60 ℃) clear paste, add ethanol 500g, mixing.Add Borneolum Syntheticum (with an amount of dissolve with ethanol, filtration), dexamethasone acetate again, laurocapram, dibutyl phthalate, glycerol, acetone, polyvinyl butyral resin add ethanol while stirring and stir evenly to 1000g, promptly get product.
Claims (2)
1, a kind of medicine for external use for the treatment of cicatrix comprises Galla Chinensis, Flos Carthami, Borneolum Syntheticum, it is characterized in that it becomes to be grouped into (percentage by weight) by following ratio:
The extract of crude drug 10～60%, Borneolum Syntheticum 0.2～1.5%, acetic acid
Dexamethasone 0.001～0.01% and remaining adjuvant;
Wherein the crude drug component is formed (part by weight) by following ratio:
Rhizoma Chuanxiong 20～40; Radix Angelicae Sinensis 10～30; Semen Persicae 10～30; Flos Carthami 5～25; Squama Manis 2～20; Olibanum 2～10; Myrrha 2～10; Radix Salviae Miltiorrhizae 30～50; Pseudobulbus cremastrae seu pleiones 15～35; Galla Chinensis 5～25; Radix Sophorae Flavescentis 10～30.
2, the medicine for external use of treatment cicatrix according to claim 1 is characterized in that adjuvant wherein becomes to be grouped into (percentage by weight) by following ratio:
Laurocapram 0.5～1.5%, polyvinyl butyral 9～12%, dibutyl phthalate 2～5%, acetone 5～10%, the ethanol of glycerol 5～10% and surplus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN96115229A CN1055855C (en) | 1996-04-12 | 1996-04-12 | External use medicine for curing scars |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN96115229A CN1055855C (en) | 1996-04-12 | 1996-04-12 | External use medicine for curing scars |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1162467A true CN1162467A (en) | 1997-10-22 |
| CN1055855C CN1055855C (en) | 2000-08-30 |
Family
ID=5122508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN96115229A Expired - Fee Related CN1055855C (en) | 1996-04-12 | 1996-04-12 | External use medicine for curing scars |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1055855C (en) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101953995A (en) * | 2010-08-09 | 2011-01-26 | 冉德学 | Keloid shrinking ointment |
| CN102091258A (en) * | 2011-03-03 | 2011-06-15 | 吴强 | Chinese medicinal composition for dispelling scars and preparation method thereof |
| CN1931241B (en) * | 2006-09-18 | 2011-10-05 | 王青年 | Chinese medicine reductant liquid for treating scar and its prepn process |
| CN102836287A (en) * | 2012-09-14 | 2012-12-26 | 河南科技大学 | Chinese medicinal ointment for treating scar and preparation method thereof |
| CN104524554A (en) * | 2014-12-22 | 2015-04-22 | 陈晨 | Medicine for eliminating scars |
| CN105535901A (en) * | 2016-01-15 | 2016-05-04 | 全书清 | Externally-applied ointment for treating keloid and preparation method of ointment |
| CN105878778A (en) * | 2016-06-29 | 2016-08-24 | 王青年 | Traditional Chinese medicine reducing solution for preventing green wound from generating scar and preparation method of traditional Chinese medicine reducing solution |
| CN105944030A (en) * | 2016-06-27 | 2016-09-21 | 王青年 | Traditional Chinese medicine restoring liquid for healing scars and acne marks |
| CN108030950A (en) * | 2018-02-07 | 2018-05-15 | 苏州元禾医疗器械有限公司 | A kind of wound dressing of dispeling scar |
| CN108721502A (en) * | 2018-08-13 | 2018-11-02 | 西安交通大学医学院第附属医院 | A kind of externally used pad pasting for treating hyperplastic scar |
| CN108939034A (en) * | 2018-09-30 | 2018-12-07 | 赵升瑞 | Scar repairing paste |
| CN110787151A (en) * | 2019-11-26 | 2020-02-14 | 大理大学 | Ligustrazine film coating agent and preparation method thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1089489A (en) * | 1993-01-04 | 1994-07-20 | 李威 | A kind of ointment for the treatment of skin scar |
| CN1044973C (en) * | 1993-11-05 | 1999-09-08 | 郑州铁路分局医院 | Burn ointment |
| CN1053820C (en) * | 1994-10-18 | 2000-06-28 | 叶太华 | Medicine for treatment of burn and scald and its preparation |
| CN1046419C (en) * | 1995-04-24 | 1999-11-17 | 刘景文 | Burn and scald curing ointment |
-
1996
- 1996-04-12 CN CN96115229A patent/CN1055855C/en not_active Expired - Fee Related
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1931241B (en) * | 2006-09-18 | 2011-10-05 | 王青年 | Chinese medicine reductant liquid for treating scar and its prepn process |
| CN101953995A (en) * | 2010-08-09 | 2011-01-26 | 冉德学 | Keloid shrinking ointment |
| CN101953995B (en) * | 2010-08-09 | 2011-11-16 | 冉德学 | Keloid shrinking ointment |
| CN102091258A (en) * | 2011-03-03 | 2011-06-15 | 吴强 | Chinese medicinal composition for dispelling scars and preparation method thereof |
| CN102091258B (en) * | 2011-03-03 | 2012-07-25 | 吴强 | Chinese medicinal composition for dispelling scars and preparation method thereof |
| CN102836287B (en) * | 2012-09-14 | 2014-02-19 | 河南科技大学 | Chinese medicinal ointment for treating scar and preparation method thereof |
| CN102836287A (en) * | 2012-09-14 | 2012-12-26 | 河南科技大学 | Chinese medicinal ointment for treating scar and preparation method thereof |
| CN104524554A (en) * | 2014-12-22 | 2015-04-22 | 陈晨 | Medicine for eliminating scars |
| CN105535901A (en) * | 2016-01-15 | 2016-05-04 | 全书清 | Externally-applied ointment for treating keloid and preparation method of ointment |
| CN105944030A (en) * | 2016-06-27 | 2016-09-21 | 王青年 | Traditional Chinese medicine restoring liquid for healing scars and acne marks |
| CN105878778A (en) * | 2016-06-29 | 2016-08-24 | 王青年 | Traditional Chinese medicine reducing solution for preventing green wound from generating scar and preparation method of traditional Chinese medicine reducing solution |
| CN108030950A (en) * | 2018-02-07 | 2018-05-15 | 苏州元禾医疗器械有限公司 | A kind of wound dressing of dispeling scar |
| CN108721502A (en) * | 2018-08-13 | 2018-11-02 | 西安交通大学医学院第附属医院 | A kind of externally used pad pasting for treating hyperplastic scar |
| CN108939034A (en) * | 2018-09-30 | 2018-12-07 | 赵升瑞 | Scar repairing paste |
| CN110787151A (en) * | 2019-11-26 | 2020-02-14 | 大理大学 | Ligustrazine film coating agent and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1055855C (en) | 2000-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1055855C (en) | External use medicine for curing scars | |
| CN109125474A (en) | A kind of silver yellow ginseng essential oil for treating solar dermatitis | |
| CN104784270A (en) | External preparation capable of relieving swelling and pain and preparation method thereof | |
| CN105055768A (en) | Traditional Chinese medicine compound external-application preparation for treating cicatrix and preparation method and application thereof | |
| CN108785357A (en) | A kind of masticinic acid and myrrh terpene compatible composition and its preparation method and application | |
| CN101810704B (en) | Combination of traditional Chinese medicine extractive with function of removing acne, preparation and use | |
| CN103751734B (en) | Blood circulation invigorating and pain relieving adhesive plaster and preparation method thereof | |
| CN104547585B (en) | The external medicine composition and preparation for the treatment of swelling and pain, edge of a knife wound and exanthemv | |
| CN101293016A (en) | Application of cistanche salsa extract in preparing medicament for treating parkinsonism | |
| CN105362410A (en) | Traditional Chinese medicine preparation for treating burn and scalds and preparation method | |
| CN103181961A (en) | Preparation method of flavonoid medicine for treating frostbite | |
| CN108392669A (en) | A kind of bioactive polysaccharide dressing and its preparation method and application for wound repair | |
| CN1895641A (en) | Medicinal preparation with blood-activating, anti-inflammatory and analgesic functions and its making method | |
| Chavan et al. | Satwa from three Tinospora species exhibits differential hepatoprotective activity against repeated acetaminophen dosing in rats | |
| CN100441206C (en) | Compound medicine for treating skin scald, insult and sore and its preparation | |
| CN100450515C (en) | Traditional Chinese medicine plaster for treating arthralgia and lumbago, and its prepn. method | |
| CN102274328B (en) | Medicament for treating psoriasis and preparation method thereof | |
| CN1052423C (en) | Medicine for treatment of uroschesis | |
| Sivagamy et al. | Wound healing activity of Indigofera enneaphylla Linn | |
| CN101757104B (en) | Medicament for treating psoriasis | |
| Shenderova | Quantitative determination of the flavonoid amount in leaves of Taraxacum officinale depending on conditions of disease | |
| CN1059807C (en) | Spur pain-removing plaster | |
| CN108653111A (en) | A kind of acne eliminating cream and preparation method thereof | |
| CN1507880A (en) | Medicinal composition for treating rheumatoid | |
| CN107875057A (en) | Cosmetic composition and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |